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ARTICLE

Acute Myeloid Leukemia

Co-administration of the mTORC1/TORC2 inhibitor INK128 and the
Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells
through Mcl-1 down-regulation and AKT inactivation

Mohamed Rahmani,1 Mandy Mayo Aust,1 Elisa Hawkins,1 Rebecca E. Parker,1 Masey Ross,1 Maciej Kmieciak,1 Leonid
Borisovich Reshko,1 Kathryn A. Rizzo,5 Catherine I. Dumur,5 Andrea Ferreira-Gonzalez,5 and Steven Grant1,2,3,4

1
Departments of Medicine; 2Biochemistry; 3Pharmacology; 4Human and Molecular Genetics; and 5Pathology, Virginia Commonwealth
University, the Virginia Institute for Molecular Medicine, and the Massey Cancer Center, Richmond, VA, USA

ABSTRACT

Effects of concurrent inhibition of mTORC1/2 and Bcl-2/Bcl-xL in human acute myeloid leukemia cells were
examined. Tetracycline-inducible Bcl-2/Bcl-xL dual knockdown markedly sensitized acute myeloid leukemia cells
to the dual TORC1/2 inhibitor INK128 in vitro as well as in vivo. Moreover, INK128 co-administered with the Bcl2/xL antagonist ABT-737 sharply induced cell death in multiple acute myeloid leukemia cell lines, including TKIresistant FLT3-ITD mutants and primary acute myeloid leukemia blasts carrying various genetic aberrations e.g.,
FLT3, IDH2, NPM1, and Kras, while exerting minimal toxicity toward normal hematopoietic CD34+ cells.
Combined treatment was particularly active against CD34+/CD38–/CD123+ primitive leukemic progenitor cells.
The INK128/ABT-737 regimen was also effective in the presence of a protective stromal microenvironment.
Notably, INK128 was more potent than the TORC1 inhibitor rapamycin in down-regulating Mcl-1, diminishing
AKT and 4EBP1 phosphorylation, and potentiating ABT-737 activity. Mcl-1 ectopic expression dramatically attenuated INK128/ABT-737 lethality, indicating an important functional role for Mcl-1 down-regulation in
INK128/ABT-737 actions. Immunoprecipitation analysis revealed that combined treatment markedly diminished
Bax, Bak, and Bim binding to all major anti-apoptotic Bcl-2 members (Bcl-2/Bcl-xL/Mcl-1), while Bax/Bak
knockdown reduced cell death. Finally, INK128/ABT-737 co-administration sharply attenuated leukemia growth
and significantly prolonged survival in a systemic acute myeloid leukemia xenograft model. Analysis of subcutaneous acute myeloid leukemia-derived tumors revealed significant decrease in 4EBP1 phosphorylation and Mcl-1
protein level, consistent with results obtained in vitro. These findings demonstrate that co-administration of dual
mTORC1/mTORC2 inhibitors and BH3-mimetics exhibits potent anti-leukemic activity in vitro and in vivo, arguing
that this strategy warrants attention in acute myeloid leukemia.

Introduction
Acute myelogenous leukemia (AML) is characterized by
frequent aberration of the PI3K/AKT/mTOR axis reflecting
various mechanisms including FLT3, Ras, and c-KIT mutations,1 PI3K delta isoform amplification,2 or autocrine IGF1/IGF-1R signaling.3 The mammalian target of rapamycin
(mTOR) is a key component of this pathway4 which integrates growth factor signals through AKT and multiple other
cellular processes.5 mTOR is a serine/threonine kinase
involved in two distinct multi-protein complexes: mTOR
complex 1 (mTORC1) and mTOR complex 2 (mTORC2).5
mTORC1 plays a central role in cap-dependent mRNA translation initiation through 4EBP1 phosphorylation, releasing
eukaryotic initiation factor eIF4E.6 mTORC1 also promotes
translation elongation by phosphorylating S6 kinase 1
(S6K1).6 mTORC2 is less studied and has distinct substrates
e.g., AKT and AGC protein kinase family members.5
Importantly, mTORC2 phosphorylates AKT at serine 473,
inducing maximal AKT activation.
First-generation agents, including rapamycin and its analogs
(rapalogs) e.g., everolimus, temsirolimus and ridaforolimus,
inhibited mTORC1 but not mTORC2. While these agents

are approved in RCC,7 leukemic activity has been minimal,8
despite evidence they target leukemia stem cells.9 Limited
rapalog activity may reflect absent (mTORC2) or incomplete
(4EBP1) target inhibition, or feedback activation of PI3K, AKT
and MEK/ERK through p70S6K and IRS1.10,11 Second generation inhibitors targeting both mTORC1 and mTORC2,
including AZD8055 and INK128, are currently undergoing
clinical evaluation. (www.clinicalTrials.gov).
Anti-apoptotic Bcl-2 members e.g., Bcl-2, Bcl-xL, and Mcl-1
are often overexpressed in hematological malignancies, including AML.12 Loss or diminished expression of pro-apoptotic Bcl2 members e.g., Bim or Bax have also been observed in many
malignancies.13 This prompted development of agents that neutralize anti-apoptotic or activate pro-apoptotic Bcl-2 members.
ABT-737 and its clinical derivative ABT-263 target Bcl-2 and
Bcl-xL, but not Mcl-1, and show significant pre-clinical
activity.14,15 ABT-199 is a BH3-mimetic that specifically targets
Bcl-2,16 and displays promising early activity in CLL17 and
AML.18 However, BH3-mimetics by themselves are unlikely to
be curative, thus arguing for rational combination strategies.
Previously, we demonstrated that combining dual
PI3K/mTOR inhibitors and Bcl-2/Bcl-xL antagonists sharply
induced cell death in diverse leukemia types in vitro and in
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vivo.19 Herein, we sought to determine whether mTOR
inhibition, which targets primitive AML progenitors,9
could similarly potentiate BH3-mimetic anti-leukemia
activity, and whether dual mTORC1/TORC2 inhibition
might provide an advantage over selective mTORC1 inhibition.

Methods
Cells
Human acute myeloid leukemia U937, KG-1 and MV4-11 cells
were as previously reported.19 MOLM-13 and OCI-AML3 cells
were purchased from DSMZ (Braunschweig, Germany). U937
cells exhibiting inducible knockdown of Bcl-2 and Bcl-xL have
been described previously.19 U937 cells stably overexpressing
wild-type Mcl-1, Bcl-2, Bcl-xL, Bax or Bak were previously
described.19

Generation of Ba/F3 mutants
Ba/F3 cells carrying FLT3 mutations were generated as described
in Online Supplementary Methods.

Stromal cells
As described in Online Supplementary Methods.

Isolation of patient-derived leukemic blast cells
These studies are sanctioned by the Virginia Commonwealth
University Investigational Review Board. Bone marrow or peripheral blood were collected with informed consent from 11 patients
with acute myeloblastic leukemia (AML) with a preponderance of
blasts (e.g., ≥ 80%). Normal hematopoietic cells were isolated
from cord blood. Mononuclear cells were isolated by FicollHypaque gradient separation as described.19

Mutation analysis
Primary AML samples were analyzed for mutations in 50 cancer
associated genes using next generation sequencing (NGS) as in
Online Supplementary methods.

Reagents
ABT-737 and ABT-199 were provided by Abbott Laboratories
(Abbott Park, IL). INK128 was purchased from ChemieTek
(Indianapolis, IN). AKT inhibitor VIII was purchased from EMD
Millipore.

Assessment of apoptosis and cell growth and viability
Apoptosis was assessed by Annexin V/PI analysis.20 Cell growth
and viability were monitored by the CellTiter-Glo Luminescent
Assay (Promega Corporation).19
Immunoprecipitation and immunoblotting were performed as
before.20,21 Primary antibodies are listed in Online Supplementary
Methods.

Subcellular fractionation
Cytosolic and membrane fractions were separated as previously
described.21

In vivo studies
These studies were approved by the Virginia Commonwealth
University Institutional Animal Care and Use Committee and conducted as previously described.19 Briefly, female NOD/SCIDgamma (Jackson laboratories) were injected intravenously via tail
vein with 5x106 luciferase-expressing U937 cells in which dual
knockdown of Bcl-2 and Bcl-xL is achieved by doxycycline. The
1554

mice were monitored using the IVIS 200 imaging system
(Xenogen Corporation, Alameda, CA), and separated into 2
groups, one of which was fed with doxycycline-supplemented
pellets (200 mg/kg, Bio-Serv, Frenchtown, NJ). Both groups were
treated with INK128 administered by gavage every 24 hours, 5
days a week. NOD/SCID-gamma mice were inoculated via tail
vein with 5x106 luciferase-expressing MV4-11 cells. 5 days later,
the mice were randomly separated into 4 groups; each group was
treated with vehicle, ABT-737 (intraperitoneal), INK128 (oral), or
ABT-737 + INK128. Tumor growth was monitored by the IVIS
200 imaging system. In some cases, female athymic nude mice
(Charles River laboratories) were injected subcutaneously in the
flank with 5 x 106 MV4-11 cells. Once tumors reached 1 cm in
diameter, the mice were treated as above, and 4 hours later tumors
were excised, lysed and subjected to Western blot analysis.
Statistical analysis is described in Online Supplementary Methods.

Results
Dual knockdown of Bcl-2/Bcl-xL markedly potentiates
the anti-leukemic activity of the mTORC1/TORC2
inhibitor INK128 in vitro and in vivo
To determine whether Bcl-2/xL inhibition sensitized
AML cells to mTOR inhibitors, U937 cells exhibiting tetinducible Bcl-2 and Bcl-xL dual knockdown were
employed. Doxycycline exposure (48 hrs) sharply downregulated both Bcl-2 and Bcl-xL. In dual knockdown cells,
the dual mTORC1/TORC2 inhibitor INK128 (50 nM) triggered rapid (e.g., within 4 hrs) and pronounced apoptosis,
reflected by caspase-3 and PARP cleavage (Figure 1A) and
cytochrome c and AIF cytosolic release (Figure 1B). In
sharp contrast, INK128 effects on caspase-3 and PARP in
cells with intact Bcl-2 and Bcl-xL were minimal. Doseresponse studies confirmed that knockdown of Bcl-2/BclxL rendered cells exquisitely sensitive to INK128-mediated lethality (Figure 1C, and Online Supplementary Figure
S1A). In contrast, effects of the selective mTORC1
inhibitor rapamycin were only modestly enhanced by
dual knockdown of Bcl-2 and Bcl-xL (Figure 1C, and
Online Supplementary Figure S1A). Notably, INK128
markedly reduced both AKT-activating sites (serine 473
and threonine 308) phosphorylation in the presence or
absence of doxycycline (Figure 1A).
In vivo studies employing a systemic xenograft mouse
model bearing luciferase-labeled U937 cells exhibiting
inducible Bcl-2/Bcl-xL dual knockdown revealed that
doxycycline significantly enhanced INK128 anti-leukemia
effects compared to controls (Figure 1D,E). Knockdown of
Bcl-2/Bcl-xL also significantly prolonged median survival
of INK128-treated mice i.e., from 14 to 21 days (P = 0.0027
log-rank test; Figure 1F). Doxycycline alone had no effect
on tumor growth or survival (Online Supplementary Figure
S1B). Finally, INK128 ± doxycycline did not induce weight
loss (Figure 1G) or other signs of toxicity. These findings
indicate that dual knockdown of Bcl-2/Bcl-xL strikingly
enhances INK128-mediated AML cell death in vitro and
inhibits AML growth while prolonging survival in vivo.

INK128/ABT-737 co-administration sharply induces
cell death in AML but not normal hematopoietic
CD34+ cells
Dose-response studies of MV4-11 and U937 cells using
a range of clinically relevant INK128 concentrations (e.g.,
50-200 nM)22 revealed that minimally toxic concentrations
of the dual Bcl-2/Bcl-xL inhibitor ABT-737 (10 nM for
haematologica | 2015; 100(12)
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MV4-11, and 500 nM for U937 cells) sharply potentiated
INK128 inhibition of cell growth and viability (Figure
2A,B). The disparate ABT-737 concentrations employed
reflect the known variability of leukemic cell vulnerability
to this agent,19,23 and were selected to achieve comparable
single-agent responses (e.g., marginal toxicity; <15% cell
death). These effects were highly synergistic by median
dose-effect analysis (Online Supplementary Figure S1C,D).
In contrast, identical concentrations of the selective
mTORC1 inhibitor rapamycin recapitulating or exceeding
clinically achievable concentrations (20 - 400 nM)24 failed
to enhance ABT-737 lethality (Figure 2A,B). Similar results
were obtained in multiple other leukemia cell lines i.e.,
MOLM-13, KG-1, and AML3 (Figure 2C). Annexin V/PI
analysis yielded equivalent results (data not shown).
INK128/ABT-737 co-exposure induced pronounced caspase-3 and PARP cleavage, whereas agents alone had minimal effects (Figure 2D). Notably, similar results were
obtained with INK128 and the selective Bcl-2 inhibitor
ABT-199 in MV4-11, MOLM-13, and KG-1 cells (Online
Supplementary Figure S1E). ABT-199 anti-leukemic activi-

A

ty was not significantly enhanced by rapamycin in these
cells (data not shown).
Parallel studies in primary blasts isolated from AML
patients (n=10), revealed that INK128/ABT-737 co-exposure was significantly more effective in diminishing cell
viability than single agents; Figure 3A (P < 0.0001). As
with cell lines, drug concentrations were selected based
upon minimal toxicity when administered alone, and clinical relevance. Furthermore, in the CD34+/CD38–/CD123+
cell population enriched for leukemia progenitor cells,25
combined treatment sharply induced cell death (Figure
3B). Interestingly, this effect appeared more pronounced
than in bulk blast populations (Figure 3B). Analysis of
three individual primary AML samples (Figure 3C)
demonstrated
increased
sensitivity
of
CD34+/CD38–/CD123+ cells compared to bulk blasts
(P=0.007). In contrast, combined treatment had no major
effect on normal hematopoietic CD34+ cells isolated from
cord blood (Figure 3B,C). Genetic analysis using next generation sequencing (NGS) revealed that the primary AML
blasts assayed carried diverse genetic aberrations including

C

E

F

D
B
G

Figure 1. Bcl-2/Bcl-xL dual knockdown strikingly enhances anti-tumor activity of INK128, but not rapamycin, in vitro as well as in vivo.
A-B. U937 cells displaying tet-inducible Bcl-2 and Bcl-xL dual knockdown were left untreated or pre-treated with 1 μg/mL doxycycline (Dox)
for 48 hrs, then exposed to 50 nM INK128 for varying intervals after which Western blot analysis was performed on whole cell lysates (A) or
on the cytosolic fractions (B). Ns = Non-specific. C) Alternatively, tet-inducible Bcl-2 and Bcl-xL U937 dual knockdown cells were treated with
the designated concentrations of INK128 or rapamycin for 24 hrs, after which cell growth and viability was assessed using the CellTiter-Glo
luminescent assay. D) NOD/SCID-gamma (NSG) mice were inoculated via the tail vein with U937 cells exhibiting tet-inducible Bcl-2/Bcl-xL dual
knockdown and expressing luciferase. 5 days following cell injection, mice were treated with 1 mg/kg INK128 in the presence (5 mice) or
absence (4 mice) of doxycycline and imaged using the IVIS 200 system. E) Quantification of the luminescent signals. Data represent the mean
± SD performed on all mice for each group. *P<0.0005. F) Kaplan-Meier survival plot. Survival curves for treatments with or without doxycycline differed very significantly e.g., P=0.0027, log-rank test. The median survival was prolonged from 14 to 21 days for mice in the presence
of doxycycline. G) Animal body weights during the course of treatment.
haematologica | 2015; 100(12)
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mutations in FLT3, IDH2, NPM1, and Kras, among others
(Figure 3D), suggesting activity across a spectrum of
leukemia types.

The INK128/ABT-737 regimen is active against AML
blasts carrying FLT3 mutations and in the presence of
a protective microenvironment
Three out of the seven characterized primary AML
specimens used carried FLT3-ITD or D835H mutations,
each of which exhibited significant sensitivity to the regimen. To test whether ABT-737/INK128 regimen is active
in FLT3 mutated AML cells, Ba/F3 cells reliant on FLT3
activation for survival were generated by transfecting
wild-type Ba/F3 cells with constructs encoding for FLT3ITD or FLT3-ITD F691L. As anticipated, FLT3-ITD Ba/F3
cells were sensitive to the FLT3 inhibitors sorafenib (20
nM) and quizartinib (10 nM), whereas FLT3-ITD F691L
displayed significant resistance to both (up to 100 nM
each; Online Supplementary Figure S2). However, while
both leukemia cells exhibited little susceptibility to
INK128 or ABT-737, combined treatment sharply
increased cell death. (Figure 4A,B). Parallel studies involving bone marrow-derived HS5 cell co-culture revealed that
combined INK128/ABT-737 treatment robustly killed
AML cells cultured with protective microenvironmental
factors (Figure 4C-D). Specifically, GFP-labeled U937 cells
co-cultured with HS-5 cells displayed a marked increase in
cell death (reflected by Annexin positivity) following combined ABT-737/INK128 exposure (Figure 4C), while
luciferase-labeled MV4-11 cells demonstrated a sharp
decline in luciferase activity (reflecting both cell viability
as well as proliferation) with combined treatment (Figure
4D). As before, drug concentrations were selected based
upon minimal toxicity alone and clinical achievability.

A

C
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INK128/ABT-737 co-administration triggers AKT
inactivation and Mcl-1 down-regulation in AML cells
U937 cell time course analysis revealed that clinically
relevant INK128 concentrations significantly reduced
AKT phosphorylation at both activating sites e.g., serine
473 and threonine 308, associated with marked translational factor 4EBP1 dephosphorylation, Mcl-1 down-regulation, and Bak up-regulation (Figure 5A,B). These events
were also observed when INK128 was combined with
ABT-737, but were not substantially greater (Figure 5A,B).
Notably, Bak was also upregulated in MV4-11 cells by
combined treatment (Online Supplementary Figure S3A). No
major changes were observed in protein levels of other
anti-apoptotic Bcl-2 family members i.e., Bcl-2 or Bcl-xL or
pro-apoptotic members i.e., Bim or Bax (Figure 5B).
Similar results were obtained in MV4-11 cells (Figure 5C),
and in primary AML blasts isolated from 2 AML patients
(Figure 5D).

Down-regulation of Mcl-1 plays a critical functional
role in INK128/ABT-737-mediated lethality, an event
that involves Bax and Bak
To determine whether Mcl-1 down-regulation contributed functionally to INK128/ABT-737 activity, U937
cells ectopically expressing Mcl-1 were employed. These
cells were significantly less susceptible to INK128/ABT737 than control pCEP4 cells, reflected by sharply reduced
Annexin V/PI positivity (Figure 6A) and caspase-3 and
PARP cleavage (Figure 6B) as well as growth inhibitory
effects (Online Supplementary Figure S3B). These findings
suggest that Mcl-1 down-regulation contributes functionally to cell death mediated by combined treatment with
INK128/ABT-737.
Parallel immunoprecipitation analysis revealed that

B

D

Figure 2. Co-administration of INK128,
but not rapamycin, with ABT-737
induces marked inhibition of cell
growth and viability in association with
pronounced induction of apoptosis in
human AML cells. A-B) U937 (A) or
MV4-11 (B) cells were exposed to the
designated concentrations of INK128
or rapamycin alone or in combination
with ABT-737 (500 nM for U937 and
10 nM for MV4-11 cells) for 24 hrs
after which cell growth and viability
were assessed using the CellTiter-Glo
Luminescent Assay. C) KG-1, MOLM13, or AML3 cells were treated with
ABT-737 (200 nM, 10 nM, 2 μM,
respectively) ± INK128 or rapamycin
(100 nM for MOLM-13, and 200 nM for
KG-1 and AML3 cells). For each cell
line, agent concentrations were selected based upon minimal toxicity (e.g.,
≤ 15% cell death when administered
alone) as well as clinical achievability.
Cells were exposed to these concentrations for 24 hrs, after which cell
growth and viability were assessed
using a CellTiter-Glo Luminescent
Assay. Error Bars: SD of 3 independent
experiments; *P<0.01 for combination vs. either agent alone.
Alternatively, cells were lysed and protein lysates were subjected to Western
Blot analysis (D).
haematologica | 2015; 100(12)
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INK128 ± ABT-737 markedly diminished Bak, Bax and
Bim binding to Mcl-1, presumably reflecting diminished
Mcl-1 protein levels (Figures 6C-E). ABT-737 or INK128
decreased Bak binding to Bcl-xL but not to Bcl-2, an effect
that was enhanced by combined treatment (Figure 6C).
However, combined treatment markedly diminished Bax
binding to both Bcl-2 and Bcl-xL, (Figure 6D). Notably, a
decline in Bax protein bound to Bcl-2 or Bcl-xL was also
observed in cells exposed to either agent alone (Figure 6D).
Finally, while INK128 increased Bim binding to Bcl-2 and
Bcl-xL, similar to our previous findings with PI3K/mTOR
inhibitors,19 ABT-737 decreased Bim binding to Bcl-2 but
not to Bcl-xL (Figure 6E). Combined treatment led to
diminished Bim/Bcl-2 binding and abrogation of INK128mediated increases in Bim/Bcl-xL binding (Figure 6E).
The role of Bax and Bak in cell death mediated by combined treatment with INK128 and ABT-737, was assessed
in Bax or Bak knockdown cells (Figure 6F). Notably, these
cells were significantly less sensitive to INK128/ABT-737
compared to non-targeted shRNA controls, reflected by

A

B

C

D

diminished Annexin V/PI positivity (Figure 6G). Similar
results were obtained in MV4-11 cells (data not shown).
Consistent with the notion that Bax, Bak, and Bim play
important roles in INK128/ABT-737 lethality, cells ectopically expressing Bcl-2 or Bcl-xL, which, like Mcl-1
sequester Bax, Bak, and Bim,19,26 were significantly less susceptible to INK128/ABT-737 (Online Supplementary Figure
S3C,D). Together, these findings suggest that Bax, Bak,
and Bim release from Bcl-2/Bcl-xL (by ABT-737 or
INK128) and Mcl-1 (by INK128) contributes to
INK128/ABT-737 anti-leukemic effects.

AKT inhibition enhances rapamycin/ABT-737 lethality
associated with Mcl-1 down-regulation
To gain insights into the disparate interactions of
INK128 and rapamycin with ABT-737, key proteins were
monitored in U937 and MV4-11 cells. In contrast to
INK128, which sharply dephosphorylated AKT and
down-regulated Mcl-1 protein levels, rapamycin failed to
diminish AKT phosphorylation or Mcl-1 protein expres-

Figure 3. Co-administration of INK128 and ABT-737 kills primary AML blasts and CD34+/CD38–/CD123+ leukemic cells while sparing normal
CD34+ progenitor cells. A) Primary AML specimens with a preponderance of blasts (e.g ≥ 80%) were isolated from 10 patients with AML
(patients 1 to 8, 10 and 11) and treated with ABT-737 (10 – 500 nM) and/or INK128 (50 – 200 nM) for 24 hrs after which cell viability was
assessed using the CellTiter-Glo Luminescent Assay. As in the case of cell lines, ABT-737 and INK128 concentrations were selected based
upon marginal toxicity when administered alone as well as clinical relevance. B) Primary AML blasts (patient 7), were treated with INK128
(200 nM) ± ABT-737 (7.5 nM) for 24 hrs, after which cell death was assessed in leukemia CD34+/CD38–/CD123+ progenitors as well as in the
bulk blast cell population using an Annexin V/7-AAD staining assay. In parallel studies, normal hematopoietic mononuclear cells isolated from
cord blood were treated with INK128 ± ABT-737 (100 nM each) and cell death was assessed in the CD34+ cell population using an Annexin
V/7-AAD staining assay. C) Additional studies using the Annexin V/7-AAD staining assay were carried out in the bulk blast populations and in
leukemia CD34+/CD38–/CD123+ progenitor cells isolated from 3 patients with AML as well as in normal hematopoietic CD34+ cells isolated
from 3 individuals. Agent concentrations were: ABT-737: 50 nM for patients 6 and 9, and 7.5 nM for patient 7; INK128: 100 nM for patients
6 and 9, and 200 nM for patient 7. For normal CD34+ cells, ABT-737 and INK128 were used at 100 nM and 200 nM, respectively. D) Mutation
analysis of primary AML specimens using targeted next-generation sequencing (NGS); only AML associated mutations are presented.
U = unknown.
haematologica | 2015; 100(12)
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sion, including at concentrations significantly higher than
achievable plasma levels24 (Figure 7A). Instead, increased
AKT phosphorylation occurred in both U937 and MV4-11
cells following a 4- or 8- hour exposure to rapamycin, consistent with previous reports11 (Figure 7A and Online
Supplementary Figure S4A,B). INK128 was more effective
than rapamycin in diminishing 4EBP1 phosphorylation as
previously reported in other cell types27 (Figure 7A).
Furthermore, co-administration of a selective AKT
inhibitor (AKT inhibitor VIII) with rapamycin/ABT-737
suppressed cell growth and viability (Figure 7B) associated
with decreased Mcl-1 protein levels (Figure 7C), comparable to findings with INK128/ABT-737. Similar results were
obtained in MV4-11 cells (Online Supplementary Figure
S4C), arguing that more pronounced AKT inactivation
and Mcl-1 down-regulation contribute to the enhanced
potentiation of ABT-737 anti-leukemic activity by INK128
compared to rapamycin.

from vehicle or single agent groups had died by day 57
(Figure 8B). Western blot analysis performed on subcutaneous tumor tissues excised from mice 4 hours post-treatment revealed that INK128 ± ABT-737 markedly diminished 4EBP1 phosphorylation and decreased Mcl-1 protein
(Figure 8C), analogous to in vitro results. Notably, the
effects of combined treatment or INK128 alone on these
proteins were similar, as shown by densitometry (Online
Supplementary Figure S4D). Significantly, combined treatment did not induce weight loss (Online Supplementary
Figure S5) or other toxicities (e.g., fur loss, behavioral
changes etc., data not shown). Together, these findings indicate that co-administration of INK128 and the BH3mimetic ABT-737 markedly reduces in vivo leukemia
growth associated with 4EBP1 dephosphorylation and
Mcl-1 down-regulation, and significantly prolongs the survival of mice bearing systemic leukemia.

Co-administration of INK128/ABT-737 markedly
decreases tumor growth in vivo and prolongs survival in
a systemic leukemia xenograft model

Discussion

To determine whether INK128/ABT-737 co-treatment
exhibited anti-leukemic activity in vivo, NOD/SCIDgamma mice bearing systemic MV4-11-derived xenografts
were employed. Combined INK128 (0.5 mg/kg) and ABT737 (80 mg/kg) treatment significantly reduced leukemia
growth (Figure 8A) and strikingly prolonged mouse survival. Moreover, on day 108 after treatment initiation,
50% of the mice treated with the combination remained
alive with healthy appearances, whereas all of the mice

A

B
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Susceptibility of various tumor types, including AML, to
BH3-mimetics like ABT-737 is regulated by Mcl-1 expression.28,29 This has prompted combination strategies to
down-regulate Mcl-1, including CDK inhibitors,30
inhibitors of translation,31 and deubiquitinase inhibition.32
Ourselves
and
others
have
reported
that
PI3K/AKT/mTOR pathway inhibition down-regulates
Mcl-1 expression19 and increases BH3-mimetic lethality.19,33,34 Rapamycin is an approved selective mTORC1
inhibitor with a relatively low toxicity profile,24 and in pre-

C

D

Figure 4. Co-administration of INK128
and ABT-737 effectively kills AML blasts
carrying FLT3 mutations or cultured in
the presence of a protective microenvironment. A) Ba/F3 cells carrying FLT3ITD or FLT3-ITD F691L were exposed to
the designated concentrations of ABT737 alone or in combination with 200
nM INK128 for 24 hrs after which cell
growth and viability were assessed
using the CellTiter-Glo Luminescent
Assay. Alternatively, protein lysates
were prepared and subjected to
Western blot analysis (B). C) U937 cells
expressing copGFP were co-cultured
with bone marrow-derived stromal HS5
cells for 24 hrs, and exposed to 200 nM
INK128 ± 500 nM ABT-737 for an additional 24 hrs. Cell death was then
assessed in cop-GFP U937 cells using
the Annexin V-APC/7-AAD staining
assay. D) MV4-11 cells expressing
luciferase were co-cultured with HS5
cells for 24 hrs and treated with INK128
(100 nM) ± ABT-737 (10 nM). After 24
hrs, a luciferase assay was performed
using D-luciferin to reflect cell growth
and viability. Error Bars: SD of 3 independent experiments; *P<0.0001 in
each case.
haematologica | 2015; 100(12)
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clinical studies targets primitive leukemia progenitors.9 In
contrast, INK128 is a novel, clinically relevant ATP-competitive dual TORC1/TORC2 inhibitor that potently
inhibits ser473 AKT phosphorylation, a process requiring
TORC2 activation.35 INK128 is effective against B-lymphoblastic leukemia cells,36 but AML activity has not been
explored. Furthermore, dual TORC1/TORC2 inhibition
by AZD8055 enhances ABT-737 lethality in malignant
epithelial cells,37,38 but this strategy has not been investigated in hematologic malignancies, including AML. Herein
we report that the novel dual TORC1/TORC2 inhibitor
INK128 potently inhibits AKT activation and triggers Mcl1 down-regulation in cultured and primary AML cells,
sharply increasing BH3 mimetic susceptibility.
The capacity of INK128 to potentiate ABT-737 antileukemic effects was greater than that of rapamycin.
Notably, disabling Bcl-2 and Bcl-xL pharmacologically by
ABT-737 or genetically by tet-inducible shRNA knockdown rendered AML cells exquisitely sensitive to INK128
but not rapamycin, suggesting that combined mTORC1
and mTORC2 inhibition is required for effective interactions. The superiority of INK128 in potentiating BH3mimetic anti-leukemic activity could reflect multiple factors. For example, rapamycin may be a less potent
inhibitor of protein translation, as suggested by its diminished inhibition of 4EBP1 phosphorylation in AML cells,
consistent with results in other malignant hematopoietic
cells.27,36 Second, in contrast to INK128, rapamycin failed
to down-regulate Mcl-1 efficiently, an action that we and
others have shown to play a key role in ABT-737 sensitivity.19,28,29 Failure of rapamycin to down-regulate Mcl-1 may

A

C
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reflect ineffective inhibition of mRNA translation39 or
other mechanisms e.g., increased Mcl-1 stability through
activation of AKT and inactivation of GSK3.40 Third,
rapamycin activates AKT through feedback mechanisms
involving p70S6K inactivation and IRS1 activation,11 raising the apoptotic threshold. Consistently, rapamycin activated AKT and did not significantly induce Mcl-1 downregulation. However, the addition of AKT inhibitor VIII to
rapamycin/ABT-737 sharply increased apoptosis in association with pronounced AKT inactivation and Mcl-1
down-regulation, as observed with INK128/ABT-737.
These findings suggest that rapamycin-mediated AKT
activation, and its failure to down-regulate Mcl-1 or
dephosphorylate 4EBP1, may contribute to minimal
rapamycin/ABT-737 interactions. In addition to Mcl-1, a
variety of AKT downstream targets might play a role in
conferring resistance to BH3-mimetics, including 4EBP1,
GSK3 and Bim, among others.19,28,29
Translation of the short-lived protein Mcl-1 is regulated
by mTORC1.41 The observation that INK128 significantly
down-regulated Mcl-1, but rapamycin exerted only modest effects, suggests that factors other than mTORC1 contribute to the marked Mcl-1 down-regulation, at least in
some cell types. These findings are consistent with recent
reports42 describing Mcl-1 down-regulation in mantle cell
lymphoma cells by dual mTORC1/TORC2 inhibitors, but
not mTORC1 inhibitors alone. However, rapamycin did
not induce significant 4EBP1 dephosphorylation, which
may lead to only partial 4EBP1/eIF4E complex dissociation, limiting effects on cap-dependent mRNA translation.
Of note, previous studies have demonstrated a prominent

B

D

Figure 5. Combined treatment with
INK128 and ABT-737 inactivates
AKT and down-regulates Mcl-1 in
AML cells. Western blot analysis in
U937 (A-B) MV4-11 (C), and primary AML blasts isolated from 2
patients (D) following exposure to
INK128 ± ABT-737 for the indicated intervals (for U937) or for 8 hrs
(MV4-11 and primary blasts). The
concentrations used in this study
were: INK128: 200 nM for U937,
100 nM for MV4-11 and patient 4,
50 nM for patient 1. ABT-737: 500
nM for U937, 10 nM for MV4-11
and patient 4, and 25 nM for
patient 1.
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Figure 6. Functional role of Mcl1, Bax, and Bak in INK128/ABT737-mediated
cell
death.
A) U937 cells ectopically
expressing Mcl-1 and their
empty vector control pCEP cells
were exposed to INK128 (200
nM) ± ABT-737 (500 nM) for
24 hrs, after which cell death
was assessed using the Annexin
V/PI staining assay. Error Bars:
SD of 3 independent experiments; *P<0.01. Alternatively,
protein lysates were prepared
and subjected to Western blot
analysis (B). (C-E) U937 cells
were treated with INK128 (200
nM) ± ABT-737 (500 nM) for
4 hrs after which cells were
lysed, Bak (C), Bax (D), or Bim
(E) were immuno-precipitated,
and the immuno-precipitates
were subjected to immunoblotting. F) Western blot analysis in
U937 cells in which Bax or Bak
was knocked down using
shRNA. G) These cells were
exposed to INK128 (200 nM) ±
ABT-737 (500 nM) for 24 hrs,
after which cell death was monitored using the Annexin V/PI
staining assay. Error Bars: SD of
3 independent experiments;
*P<0.01 for shBax and P<0.05
for shBak.

C
U937 24hrs

U937 8hrs

Figure 7. Inhibition of AKT enhances
rapamycin/ABT-737 lethality in association with
Mcl-1 down-regulation. A) U937 or MV4-11 cells
were exposed to the designated concentrations of
rapamycin or INK128 for 8 hrs, after which cells
were lysed and protein lysates were subjected to
Western blot analysis. B-C) Cell growth and viability (B) or Western blot analysis (C) performed in
U937 cells following exposure to the indicated
agents for 24 hrs or 8 hrs, respectively. The concentrations used in this study were: 500 nM ABT737; 200 nM INK; 20 nM rapamycin; and 2 μM
AKTi (AKT inhibitor VIII). **P<0.001; *P<0.02.
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A

B

C

Figure 8. Co-administration of INK128 and ABT-737 exhibits potent in vivo anti-leukemia activity. (A) NOD/SCID-gamma mice were inoculated
via tail-vein with MV4-11 cells expressing luciferase. Five days later, mice were treated with INK128 (0.5 mg/kg) ± ABT-737 (80 mg/kg) and
imaged using the IVIS 200 system (A), and survival was analyzed using Kaplan-Meier survival plots (B). Studies involved 5-6 mice per condition; the survival of mice treated with the combination was significantly prolonged compared to mice treated with single agents (P=0.0011,
and P=0.0007 for combination vs. ABT-737 or INK128 respectively, log-rank test). Treatment was discontinued on day 70. On day 108, 2 mice
were still alive with healthy appearances; on the same day, the experiment was terminated. C) Nude mice were injected subcutaneously with
MV4-11 cells. Once the tumors reached 1 cm in diameter, mice were treated with INK128 (0.5 mg/kg) ± ABT-737 (80 mg/kg). 4 hrs later,
tumors were excised, lysed and analyzed by Western blot analysis.

role for eIF4E in controlling Mcl-1 translation.43 It is also
possible that mTORC2 inhibition potentiates Mcl-1
down-regulation through AKT inactivation, GSK3 activation, and MCL-1 degradation.40 The observation that
enforced Mcl-1 expression markedly diminished
INK128/ABT-737-mediated apoptosis indicate that Mcl-1
down-regulation contributes functionally to cell death,
consistent with previous findings from our group and others that Mcl-1 plays a critical role in determining ABT-737
sensitivity.19 Significantly, Mcl-1 down-regulation was similar following exposure to INK128 alone or ABT737/INK128, whereas cell death was considerably more
pronounced with combined treatment. This suggests that
Mcl-1 down-regulation is not solely responsible for the
observed cell death, but may cooperate with Bcl-2 and BclxL inhibition. However, the observation that similar interactions occurred with ABT-199, which inhibits Bcl-2 but
haematologica | 2015; 100(12)

not Bcl-xL,16 suggest that Bcl-2 inhibition may be particularly important in some AML cells.
Recent studies have highlighted interactions between
anti- and pro-apoptotic Bcl-2 proteins in cell fate.19,44
Combined INK128/ABT-737 treatment not only diminished Mcl-1 protein levels, but also markedly reduced Bax,
Bak, and Bim binding to Mcl-1 and Bcl-xL. Combined
treatment also significantly decreased Bax/Bcl-2 and
Bim/Bcl-2 binding, collectively leading to increased free
Bax, Bak, and Bim, culminating in apoptosis. This interpretation is supported by evidence that Bax or Bak knockdown, or ectopic expression of Mcl-1, Bcl-2, or Bcl-xL, significantly diminished INK128/ABT-737 lethality. Notably,
INK128 decreased Bak binding to Bcl-xL and Bax binding
to Bcl-2 and Bcl-xL, consistent with our previous findings
with PI3K inhibitors.19 The mechanism underlying this
phenomenon could reflect the observed increase in Bim
1561
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binding to Bcl-2 and Bcl-xL which would displace Bax and
Bak from these anti-apoptotic proteins. Together, these
findings support a model wherein INK128/ABT-737 coadministration induces multiple perturbations that cooperatively induce cell death, including AKT inactivation,
4EBP1 dephosphorylation, Mcl-1 down-regulation, and
Bax, Bak, and Bim release from all the major pro-apoptotic
Bcl-2 members e.g., Bcl-2, Bcl-xL, and Mcl-1.
Combined INK128/ABT-737 treatment significantly
increased cell death in primary blast specimens isolated from
multiple AML patients. These samples exhibited diverse
genetic aberrations including mutations in FLT3 (FLT3-ITD
or FLT3-D835H), Kras, IDH2 (R140Q, R172K), and NPM1
(p.W288fs*12). Significant heterogeneity occurred in primary AML cell responses to this regimen, as with AML
lines, in that some specimens responded to very low ABT737 concentrations (e.g., 7.5 - 10 nM) while others required
significantly higher concentrations (e.g., 500 nM), although
the latter were equivalent to pharmacologically achievable
concentrations of the clinically relevant ABT-263. These
observations are consistent with previous reports from our
and other groups.19,23 The molecular basis for this heterogeneity is unknown, but may stem from intrinsic disparities
in Bcl-2 family protein expression as reflected by BH3-profiling.45 In this regard, AML cells with defined genetic backgrounds e.g., MLL translocation or IDH1/2 mutations, are
highly sensitive to Bcl-2 inhibition.46,47 Differential sensitivity
of cell lines and primary specimens to INK128 also occurred,
perhaps reflecting dependence of a particular leukemic cell
on the mTOR pathway and/or activation of compensatory
survival pathways.
Interestingly, ABT-737/INK128 regimen activity was, if
anything, more pronounced in CD34+/CD38–/CD123+
populations enriched in leukemia progenitor cells than in
bulk blast populations. These findings are consistent with
evidence that primitive blast progenitors may be particularly susceptible to Bcl-2/Bcl-xL inhibitors such as ABT737,28 or to rapalogs9 when administered individually.
Despite pronounced resistance of Ba/F3 leukemia cells
expressing FLT3-ITD to the Bcl-2 antagonist ABT-737,
these cells were very sensitive to combined ABT737/INK128 exposure. Furthermore, FLT3-ITD F691L
mutants exhibiting marked resistance to FLT3 inhibitors
e.g., sorafenib or quizartinib were also susceptible to combined treatment. The ability of INK128/ABT-737 to kill
leukemia cells regardless of upstream FLT3 status may
reflect disruption of critical cell survival factors
downstream of this genetic aberration. In this regard,
recent studies suggest that Mcl-1 represents a critical survival factor for FLT3-ITD leukemias.48 It is noteworthy
that the INK128/ABT-737 regimen effectively killed
leukemia cells in the presence of a protective microenvi-

References
1. Martelli AM, Evangelisti C, Chiarini F,
Grimaldi C, Manzoli L, McCubrey JA.
Targeting the PI3K/AKT/mTOR signaling
network in acute myelogenous leukemia.
Expert Opin Investig Drugs. 2009;
18(9):1333-1349.
2. Sujobert P, Bardet V, Cornillet-Lefebvre P, et
al. Essential role for the p110delta isoform
in phosphoinositide 3-kinase activation and

1562

ronment e.g., HS5 cells, suggesting that this regimen
might circumvent bone marrow stromal cell protective
effects, known to play an important role in leukemia cell
survival. Microenvironmental factors have also been postulated to contribute to leukemic cell resistance to various
therapies, including cytotoxic agents.49 Moreover, the
PI3K/mTOR inhibitor BEZ235 combined with the HDACI
panobinostat circumvented stromal cell resistance of diffuse large B-cell lymphoma cells through a mechanism
involving Mcl-1 down-regulation and Bim up-regulation.50
Studies are currently underway to determine whether
such mechanisms are operative in the present setting.
Whatever the mechanism, the ability of the ABT737/INK128 regimen to trigger cell death and/or diminish
survival in AML cells co-cultured with stromal cells argues
that this strategy may be able to bypass survival signals
conferred by the microenvironment.
In vivo studies employing a mouse model bearing a systemic U937 xenograft exhibiting tet-inducible Bcl-2 and BclxL dual knockdown demonstrated that disabling Bcl-2 and
Bcl-xL markedly increased INK128 anti-leukemic activity
and significantly prolonged survival. Furthermore
INK128/ABT-737 co-administration significantly reduced
leukemia growth and prolonged survival in a systemic
xenograft mouse model without exerting significant toxicity.
Such findings are concordant with evidence that both of
these agents preferentially target neoplastic cells, and particularly leukemia stem cells.9,28 Significantly, several
INK128/ABT-737 regimen actions observed in vitro were
recapitulated in a subcutaneous xenograft model, including
4EBP1 dephosphorylation, and Mcl-1 down-regulation. The
relative lack of toxicity in vivo is compatible with the observation that the INK128/ABT-737 regimen was minimally
toxic to normal CD34+ cells at exposures that induced
marked cell death in their leukemic counterparts. Taken
together, these findings demonstrate that combined treatment with INK128 and BH3-mimetics such as ABT-737
robustly kills diverse myeloid leukemia cells in vitro as well as
in vivo through a mechanism involving Mcl-1 down-regulation and Bax/Bak activation. They also raise the possibility
that combining a dual mTORC1/mTORC2 inhibitor such as
INK128 with a BH3-mimetic such as ABT-263 or ABT-199
may be particularly effective in the setting of AML.
Funding
This work was supported by CA167708, CA142509, and
Leukemia and Lymphoma Society of America award #6472-15.
Authorship and Disclosures
Information on authorship, contributions, and financial & other
disclosures was provided by the authors and is available with the
online version of this article at www.haematologica.org.

cell proliferation in acute myeloid
leukemia. Blood. 2005;106(3):1063-1066.
3. Chapuis N, Tamburini J, Cornillet-Lefebvre
P, et al. Autocrine IGF-1/IGF-1R signaling is
responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic
value of neutralizing anti-IGF-1R antibody.
Haematologica. 2010;95(3):415-423.
4. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 2005;8(3):179183.
5. Zoncu R, Efeyan A, Sabatini DM. mTOR:

from growth signal integration to cancer,
diabetes and ageing. Nat Rev Mol Cell Biol.
2011;12(1):21-35.
6. Laplante M, Sabatini DM. mTOR signaling
at a glance. J Cell Sci. 2009;122(Pt 20):35893594.
7. Kwitkowski VE, Prowell TM, Ibrahim A, et
al. FDA approval summary: temsirolimus
as treatment for advanced renal cell carcinoma. Oncologist. 2010;15(4):428-435.
8. Chapuis N, Tamburini J, Green AS, et al.
Perspectives on inhibiting mTOR as a future

haematologica | 2015; 100(12)

mTORC1/TORC2 and Bcl-2/Bcl-xL inhibition in leukemia

9.

10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

treatment strategy for hematological malignancies. Leukemia. 2010;24(10):1686-1699.
Xu Q, Thompson JE, Carroll M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood.
2005;106(13):4261-4268.
Carracedo A, Ma L, Teruya-Feldstein J, et
al. Inhibition of mTORC1 leads to MAPK
pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin
Invest. 2008;118(9):3065-3074.
O'Reilly KE, Rojo F, She QB, et al. mTOR
inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.
Cancer Res. 2006;66(3):1500-1508.
Shangary S, Johnson DE. Recent advances
in the development of anticancer agents
targeting cell death inhibitors in the Bcl-2
protein family. Leukemia. 2003;17(8):14701481.
Strasser A, Cory S, Adams JM. Deciphering
the rules of programmed cell death to
improve therapy of cancer and other diseases. EMBO J. 2011;30(18):3667-3683.
Oltersdorf T, Elmore SW, Shoemaker AR,
et al. An inhibitor of Bcl-2 family proteins
induces regression of solid tumours.
Nature. 2005;435(7042):677-681.
Tse C, Shoemaker AR, Adickes J, et al.
ABT-263: a potent and orally bioavailable
Bcl-2 family inhibitor. Cancer Res.
2008;68(9):3421-3428.
Souers AJ, Leverson JD, Boghaert ER, et al.
ABT-199, a potent and selective BCL-2
inhibitor, achieves antitumor activity while
sparing platelets. Nat Med. 2013;19(2):202208.
Ng SY, Davids MS. Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia
and non-Hodgkin lymphoma. Clin Adv
Hematol Oncol. 2014;12(4):224-229.
Konopleva M, Polleya DA, Potluri J, et al. A
Phase 2 Study of ABT-199 (GDC-0199) in
Patients with Acute Myelogenous
Leukemia (AML). Blood. 2014;124(21):118.
Rahmani M, Aust MM, Attkisson E,
Williams DC, Jr., Ferreira-Gonzalez A,
Grant S. Dual inhibition of Bcl-2 and Bcl-xL
strikingly enhances PI3K inhibitioninduced apoptosis in human myeloid
leukemia cells through a GSK3- and Bimdependent mechanism. Cancer Res. 2013;
73(4):1340-1351.
Rahmani M, Dai Y, Grant S. The histone
deacetylase inhibitor sodium butyrate
interacts synergistically with phorbol
myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human
myeloid leukemia cells through a tumor
necrosis factor-alpha-mediated process.
Exp Cell Res. 2002;277(1):31-47.
Rahmani M, Davis EM, Bauer C, Dent P,
Grant S. Apoptosis induced by the kinase
inhibitor BAY 43-9006 in human leukemia
cells involves down-regulation of Mcl-1
through inhibition of translation. J Biol
Chem. 2005;280(42):35217-35227.
Infante JR, Tabernero J, Burris HA, et al. A
phase I, open label, dose escalation study of
an oral mammalian target of rapamycin
inhibitor INK128 administered once daily
in patients with advanced malignancies.

haematologica | 2015; 100(12)

23.

24.

25.

26.

27.
28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

Cancer Res. 2012;72(8 Suppl):Abstract nr
5588.
Zhang W, Ruvolo VR, Gao C, et al.
Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and
Bcl-2 in human acute myelogenous
leukemia cells. Mol Cancer Ther. 2014;
13(7):1848-1859.
Jimeno A, Rudek MA, Kulesza P, et al.
Pharmacodynamic-guided modified continuous reassessment method-based, dosefinding study of rapamycin in adult patients
with solid tumors. J Clin Oncol.
2008;26(25):4172-4179.
Pan R, Hogdal LJ, Benito JM, et al. Selective
BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.
Cancer Discov. 2014;4(3):362-375.
Willis SN, Chen L, Dewson G, et al.
Proapoptotic Bak is sequestered by Mcl-1
and Bcl-xL, but not Bcl-2, until displaced by
BH3-only proteins. Genes Dev. 2005;
19(11):1294-1305.
Maiso P, Liu Y, Morgan B, et al. Defining
the role of TORC1/2 in multiple myeloma.
Blood. 2011;118(26):6860-6870.
Konopleva M, Contractor R, Tsao T, et al.
Mechanisms of apoptosis sensitivity and
resistance to the BH3 mimetic ABT-737 in
acute myeloid leukemia. Cancer Cell. 2006;
10(5):375-388.
van Delft MF, Wei AH, Mason KD, et al.
The BH3 mimetic ABT-737 targets selective
Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
Cancer Cell. 2006;10(5):389-399.
Chen S, Dai Y, Harada H, Dent P, Grant S.
Mcl-1 down-regulation potentiates ABT737 lethality by cooperatively inducing Bak
activation and Bax translocation. Cancer
Res. 2007;67(2):782-791.
Zhang W, Konopleva M, Ruvolo VR, et al.
Sorafenib induces apoptosis of AML cells
via Bim-mediated activation of the intrinsic
apoptotic pathway. Leukemia. 2008;
22(4):808-818.
Schwickart M, Huang X, Lill JR, et al.
Deubiquitinase USP9X stabilizes MCL1
and promotes tumour cell survival. Nature.
2010;463(7277):103-107.
Jin L, Tabe Y, Kojima K, et al. PI3K inhibitor
GDC-0941 enhances apoptotic effects of
BH-3 mimetic ABT-737 in AML cells in the
hypoxic bone marrow microenvironment. J
Mol Med. 2013;91(12):1383-1397.
Vaillant F, Merino D, Lee L, et al. Targeting
BCL-2 with the BH3 mimetic ABT-199 in
estrogen receptor-positive breast cancer.
Cancer Cell. 2013;24(1):120-129.
Sarbassov DD, Guertin DA, Ali SM,
Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307(5712):1098-1101.
Janes MR, Vu C, Mallya S, et al. Efficacy of
the investigational mTOR kinase inhibitor
MLN0128/INK128 in models of B-cell acute
lymphoblastic leukemia. Leukemia. 2013;
27(3):586-594.
Faber AC, Coffee EM, Costa C, et al.
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by sup-

38.

39.

40.

41.

42.

43.

44.

45.

46.

47.

48.

49.
50.

pressing MCL-1. Cancer Discov. 2014;4(1):
42-52.
Preuss E, Hugle M, Reimann R, Schlecht M,
Fulda S. Pan-mammalian target of
rapamycin (mTOR) inhibitor AZD8055
primes rhabdomyosarcoma cells for ABT737-induced apoptosis by down-regulating
Mcl-1 protein. J Biol Chem. 2013;
288(49):35287-35296.
Tamburini J, Green AS, Bardet V, et al.
Protein synthesis is resistant to rapamycin
and constitutes a promising therapeutic target in acute myeloid leukemia. Blood. 2009;
114(8):1618-1627.
Maurer U, Charvet C, Wagman AS,
Dejardin E, Green DR. Glycogen synthase
kinase-3 regulates mitochondrial outer
membrane permeabilization and apoptosis
by destabilization of MCL-1. Mol Cell.
2006;21(6):749-760.
Mills JR, Hippo Y, Robert F, et al. mTORC1
promotes survival through translational
control of Mcl-1. Proc Natl Acad Sci USA.
2008;105(31):10853-10858.
Muller A, Zang C, Chumduri C, Dorken B,
Daniel PT, Scholz CW. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced
apoptosis by down-regulation of Mcl-1 in
mantle cell lymphoma. Int J Cancer. 2013;
133(8):1813-1824.
Hsieh AC, Costa M, Zollo O, et al. Genetic
dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell.
2010;17(3):249-261.
Morales AA, Kurtoglu M, Matulis SM, et al.
Distribution of Bim determines Mcl-1
dependence or codependence with BclxL/Bcl-2 in Mcl-1-expressing myeloma
cells. Blood. 2011;118(5):1329-1339.
Deng J, Carlson N, Takeyama K, Dal Cin P,
Shipp M, Letai A. BH3 profiling identifies
three distinct classes of apoptotic blocks to
predict response to ABT-737 and conventional chemotherapeutic agents. Cancer
Cell. 2007;12(2):171-185.
Chan SM, Thomas D, Corces-Zimmerman
MR, et al. Isocitrate dehydrogenase 1 and 2
mutations induce BCL-2 dependence in
acute myeloid leukemia. Nat Med. 2015;
21(2):178-184.
Niu X, Wang G, Wang Y, et al. Acute
myeloid leukemia cells harboring MLL
fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to
the Bcl-2-selective inhibitor ABT-199.
Leukemia. 2014;28(7):1557-1560.
Kasper S, Breitenbuecher F, Heidel F, et al.
Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies.
Blood Cancer J. 2012;2(3):e60.
Klemm F, Joyce JA. Microenvironmental
regulation of therapeutic response in cancer. Trends Cell Biol. 2014; 25(4);198-213
Rahmani M, Aust MM, Benson EC,
Wallace L, Friedberg J, Grant S.
PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells
through BIM- and MCL-1-dependent
mechanisms in vitro and in vivo. Clin
Cancer Res. 2014;20(18):4849-4860.

1563

